Consumer medical giant Bausch + Lomb may be preparing to sell off its eye care business, which would include contact lens manufacturing taking place in Rochester, N.Y.
The Financial Times wrote Sept. 16 that the sale would settle debts for its parent company, Bausch Health. Bausch is working with advisers from Goldman Sachs to explore interest from potential buyers. It would be an expensive deal, with Bausch + Lomb's enterprise value placed at about $10 billion, according to FT. It's expected to post $4.7 billion in sales for 2024. Bausch Health has accrued debts of more than $20 billion.
Bausch + Lomb told FT it declined to comment.
Bausch's North American manufacturing operations include vision, medical/surgical and consumer health care businesses. Its Rochester plant had a 115,000-square-foot expansion in 2021 with "state-of-the-art production lines" for daily disposable contact lenses.
At that time, B+L President Joe Gordon told local TV station WXXI that the Rochester plant was vital and would continue to operate even if the division was sold off.
"It goes hand in hand with Rochester. Our Bausch + Lomb mission is to help patients see better to live better, and Rochester is a poster child for us on how we're accomplishing our mission."